KoreaMed Synapse
 
About Synapse
Overview
Help
Disclaimer
Advanced Search
 
 
   
       Journal List > Yonsei Med J > v.48(4); Aug 2007
  |    |  Full-text      |    |  
Yonsei Med J. 2007 Aug;48(4):586-594.
Published online 2007 August 20.  doi: 10.3349/ymj.2007.48.4.586.
Copyright © 2007 The Yonsei University College of Medicine
Avian Influenza: Should China Be Alarmed?
Zhaoliang Su Huaxi Xu, and Jianguo Chen
Department of Microbiology and Immunology, Institute of Clinical Laboratory Medicine, Jiangsu University, Zhenjiang, China.

Reprint address: requests to Dr. Huaxi Xu, School of Medical Technology, Jiangsu University, Xuefu Road 301, Zhenjiang City, Jiangsu Province, China, 212013. Tel: 86-511-5038140, Fax: 86-511-5038449, Email: xuhx@ujs.edu.cn or Email: szl30@yeah.net
Received March 27, 2007; Accepted April 24, 2007.

Abstract

Avian influenza has emerged as one of the primary public health concern of the 21st century. Influenza strain H5N1 is capable of incidentally infecting humans and other mammals. Since their reemergence in 2003, highly pathogenic avian influenza A (H5N1) viruses have been transmitted from poultry to humans (by direct or indirect contact with infected birds) in several provinces of Mainland China, which has resulted in 22 cases of human infection and has created repercussions for the Chinese economy. People have been concerned whether a new pandemic will occur in the future. The eradication of pathogenic avian influenza viruses appears to be the most effective way to prevent an influenza pandemic. This paper will examine the features of H5N1, including incidence, infection, immunity, clinical management, prevention and control, and therapy in Mainland China.

Keywords: Avian influenza, H5N1, innate immune, adaptive immune, prevention, control.
References
1. Zhang M. Chinese economic loss USD 87,000,000,000 because for avian influenza Oriental Morning Post. 2005 [Nov 22].
Available from http://finance.sina.com.cn/g/20051122/07132136780.shtml. Chinese
2. Lahariya C,Sharma AK,Pradhan SK. Avian flu and possible human pandemic. Indian Pediatr 2006;43:317–325.
3. Horimoto T,Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 2005;3:591–600.
4. Xu XY,Wang QH. Biology and epidemiology of avian influenza; Zhonghua Yi Xue Za Zhi. 2004. pp. 353-354.
5. Liu JP. Avian influenza-a pandemic waiting to happen?. J Microbiol Immunol Infect 2006;39:4–10.
6. Beijing Centers for Diseases Control and Prevention & Centers Preventive Medical ResearchSchematic diagram of avian influenza subtypes virus. Xinhua News Agency. 2006 [Feb 21].
Aviable from http://news.sina.com.cn/c/p/2006-02-21/20219164152.shtml. Chinese
7. Subbarao K,Klimov A,Katz J,Regnery H,Lim W,Hall H,et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393–396.
8. Claas EC,Osterhaus AD,van Beek R,De Jong JC,Rimmelzwaan GF,Senne DA,et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351:472–477.
9. Chen H,Deng G,Li Z,Tian G,Li Y,Jiao P,et al. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 2004;101:10452–10457.
10. Xing L. The Chinese avian influenza case presentd disperse and Ministry of Public Health asked to make careful obviate chinanews.com. 2006 [April 28].
Available from http://www.chinanews.com.cn//news/2006/2006-04-28/8/724249.shtml.Chinese
11. The news office of State councilthe Chinese avian influenza epidemic characteristics, prevention and control measures. 2006 [Feb 5].
Available from http:// www.wxhealth.com/qlg/q43.htm.Chinese
12. Perez DR,Sorrell EM,Donis RO. Avian influenza: an omnipresent pandemic threat. Pediatr Infect Dis J 2005;24(11 Suppl):S208–S216.
13. Luo RP,Zhu YM,Xu ZY,Gao JP,Yu SJ. Report of the first human case of H5N1 avian influenza pneumonia in Human, China. Zhonghua Er Ke Za Zhi 2006;44:342–345.
Chinese
14. Yu HJ,Chen YX,Shu YL,Li JH,Gao ZC,Hu SX,et al. The first confirmed human case of avian influenza A (H5N1) in Mainland, China. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:281–287.
15. Ministry of Public HealthThe bulletin of human avian influenza cases in mainland china.
Available from http://news.tom.com/hot/qinliugan/.Chinese
16. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO.world health organization. 2006 [May 19].
Available from http://www.who.int/csr/disease/avian_influenza/country/en/.Chinese
17. Bridges CB,Kuehnert MJ,Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094–1101.
18. Liao DJ,Song B. Review and Epidemiology of Avian Influenza [In Chinese]. J Vet Parasitol 2004;12:43–47.
19. Ungchusak K,Auewarakul P,Dowell SF,Kitphati R,Auwanit W,Puthavathana P,et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352:333–340.
20. Zhang CY,Wei JF,He SH. Adaptive evolution of the spike gene of SARS coronavirus: changes in positively selected sites at different epidemic groups. BMC Microbiol 2006;6:88.
21. Nash T. Immunity to viruses. In: Roitt I,Brostoff J,Male DImmunology. 6th ed. Harcourt Asia: Pte Ltd; 2001. pp. 236-237.
22. Sekellick MJ,Carra SA,Bowman A,Hopkins DA,Marcus PI. Transient resistance of influenza virus to interferon action attributed to random multiple packaging and activity of NS genes. J Interferon Cytokine Res 2000;20:963–970.
23. Engelhardt OG,Sirma H,Pandolfi PP,Haller O. Mx1 GTPase accumulates in distinct nuclear domains and inhibits influenza A virus in cells that lack promyelocytic leukaemia protein nuclear bodies. J Gen Virol 2004;85:2315–2326.
24. Suarez DL,Schultz-Cherry S. Immunology of avian influenza virus: a review. Dev Comp Immunol 2000;24:269–283.
25. Lipatov AS,Andreansky S,Webby RJ,Hulse DJ,Rehg JE,Krauss S,et al. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: the role of cytokines and B- and T-cell responses. J Gen Virol 2005;86:1121–1130.
26. Hsieh SM,Chang SC. Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus. J Immunol 2006;176:4530–4533.
27. Ko SY,Ko HJ,Chang WS,Park SH,Kweon MN,Kang CY. Alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005;175:3309–3317.
28. van Riel D,Munster VJ,de Wit E,Rimmelzwaan GF,Fouchier RA,Osterhaus AD,et al. H5N1 virus attachment to lower respiratory tract. Science 2006;312:399.
29. Tumpey TM,García-Sastre A,Taubenberger JK,Palese P,Swayne DE,Pantin-Jackwood MJ,et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005;79:14933–14944.
30. Seo SH,Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001;75:2516–2525.
31. Cavanagh LL,Bonasio R,Mazo IB,Halin C,Cheng G,van der Velden AW,et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 2005;6:1029–1037.
32. Belz GT,Wilson NS,Smith CM,Mount AM,Carbone FR,Heath WR. Bone marrow-derived cells expand memory CD8+ T cells in response to viral infections of the lung and skin. Eur J Immunol 2006;36:327–335.
33. Belz GT,Smith CM,Eichner D,Shortman K,Karupiah G,Carbone FR,et al. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004;172:1996–2000.
34. Flynn KJ,Riberdy JM,Christensen JP,Altman JD,Doherty PC. In vivo proliferation of naive and memory influenza-specific CD8+ T cells. Proc Natl Acad Sci U S A 1999;96:8597–8602.
35. Jelley-Gibbs DM,Brown DM,Dibble JP,Haynes L,Eaton SM,Swain SL. Unexpected prolonged presentation of influen za antigens promotes CD4 T cell memory generation. J Exp Med 2005;202:697–706.
36. Jameson J,Cruz J,Terajima M,Ennis FA. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999;162:7578–7583.
37. Laudert E,Sivanandan V,Halvorson D. Effect of an H5N1 avian influenza virus infection on the immune system of mallard ducks. Avian Dis 1993;37:845–853.
38. Sakai K,Yada K,Sakabe G,Tani O,Miyaji K,Nakamura M,et al. Serological and virological studies of Newcastle disease and avian influenza in slaughter-age ostriches (Struthio camelus) in Japan. J Vet Med Sci 2006;68:491–494.
39. Rott R,Klenk HD,Nagai Y,Tashiro M. Influenza viruses, cell enzymes, and pathogenicity. Am J Respir Crit Care Med 1995;152:S16–S19.
40. Lipatov AS,Gitel'man AK,Govorkova EA,Smirnov IuA. Changes in biological and physico-chemical properties of avian influenza virus A hemagglutinin H2 during adaptation to a new host. Vopr Virusol 1995;40:208–211.
41. Matrosovich M,Zhou N,Kawaoka Y,Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999;73:1146–1155.
42. Bender C,Hall H,Huang J,Klimov A,Cox N,Hay A,et al. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 1999;254:115–123.
43. Stevens J,Blixt O,Tumpey TM,Taubenberger JK,Paulson JC,Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006;312:404–410.
44. Il'iushina NA,Rudneva IA,Varich NL,Lipatov AS,Webster RG,Kaverin NV. Antigenic structure of influenza A virus subtype H5 hemagglutinin: mechanism of acquiring stability to monoclonal antibodies in escape-mutants. Mol Gen Mikrobiol Virusol 2003;1:40–45.
45. Chen H,Subbarao K,Swayne D,Chen Q,Lu X,Katz J,et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003;21:1974–1979.
46. Chen Z,Matsuo K,Asanuma H,Takahashi H,Iwasaki T,Suzuki Y,et al. Enhanced protection against a lethal infuenza virus challenge by immunization with both hemagglutinin and neuraminidase-expressing DNAs. Vaccine 1999;17:653–659.
47. Frace AM,Klimov AI,Rowe T,Black RA,Katz JM. Modified M2 proteins produce heterotypic immunity against infuenza A virus. Vaccine 1999;17:2237–2244.
48. Liu W,Zou P,Ding J,Lu Y,Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005;7:171–177.
49. Renegar KB. Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci 1992;42:222–232.
50. World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005;11:1515–1521.
51. Liu JP. Avian influenza--a pandemic waiting to happen?. J Microbiol Immunol Infect 2006;39:4–10.
52. Fernandez-Sesma A,Marukian S,Ebersole BJ,Kaminski D,Park MS,Yuen T,et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 2006;80:6295–6304.
53. Perdue ML. Naturally occurring NS gene variants in an avian influenza virus isolate. Virus Res 1992;23:223–240.
54. Chen H,Smith GJ,Li KS,Wang J,Fan XH,Rayner JM,et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006;103:2845–2850.
55. Henley E. The growing threat of avian influenza. J Fam Pract 2005;54:442–444.
56. Riedel S. Crossing the species barrier: the threat of an avian influenza pandemic. Proc (Bayl Univ Med Cent) 2006;19:16–20.
57. Yu SY,Chen Q,Hu GF. Summary of Guangdong provincial seminar on avian influenza and influenza. Di Yi Jun Yi Da Xue Xue Bao 2005;25:1587–1588.
58. Normile D. Avian influenza. Chinese Ministry questions bird flu findings. Science 2005;309:364.
59. Yang YH. Pay enough attention to human infection with avian influenza virus. Zhonghua Er Ke Za Zhi 2004;42:246–247.
60. Chinese Ministry of Public HealthDiagnosis and treatment measures about human influenza A. 2005 [Sep 5].
Available from http://www.cintcm.com/qinliugan/index_qlg.htm
61. How to prevent avian influenza of citizen. Shanghai Evening Post. 2004 [Jan 29].
Available from http://www.china.com.cn/chinese/zhuanti/qlg/487001.htm.Chinese
62. Wei TB,Huang YT,Li KS. Influenza virus variation and prevention. Chin J Immunol 2006;22:16–19.
Chinese
63. Jin NY. Prevalence and preventive control of highly pathogenic avian influenza. Chin J Immunol 2006;22:5–12.
Chinese
64. Hang J. Xinhuanet. Chinese: 2006 [June 14]. My country had successfully advanced development three kinds of new influenza vaccines.
65. Cyranoski D. China steps up drive to vaccinate all domestic birds. Nature 2005;438:406.
66. Wood JM,Nicholson KG,Stephenson I,Zambon M,Newman RW,Major DL,et al. Experience with the clinical development of influenza vaccines for potential pandemics. Med Microbiol Immunol 2002;191:197–201.
67. The Chinese Center for Disease Control and PreventionThe project of human avian influenza's diaginosis and treatment.
2005 Revised edition
Available from http://www.chinacdc.net.cn/n272442/n272530/n273736/n273781/n305111/index.html
68. Prevention and control of avian influenza in humans in China: achieving the national objectives of the WHO Global Influenza Preparedness Plan Weekly epidemiological record. 2006. pp. 105-116.
Available from http://www.who.int/wer
69. Hu X. Speech at the International Conference on Avian Influenza; Geneva. 2005.
70. Leneva IA,Roberts N,Govorkova EA,Goloubeva OG,Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101–115.
71. World Health OrganizationAvian influenza (bird flu) fact sheet. 2006 [Accessed on February 24].
At http://www.who.int/mediacentre/factsheets/ avian_influenza/en/index.html
72. Avian influenza A (H5N1). Weekly Epidemiol Rec 2004;79:65–70.
(Also available at http://www.who.int/wer/2004/en/wer7907.pdf. (Accessed on February 24, 2006)
73. Chotpitayasunondh T,Ungchusak K,Hanshaoworakul W,Chunsuthiwat S,Sawanpanyalert P,Kijphati R,et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201–209.
74. Aoki FY,Macleod MD,Paggiaro P,Carewicz O,El Sawy A,Wat C,et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123–129.
75. Hedrick JA,Barzilai A,Behre U,Henderson FW,Hammond J,Reilly L,et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410–417.
76. Hughes JM. Twenty-first century plague; The story of SARS. J Clin Invest 2006;116:846.